stock
ASPE · Aspen Neuroscience, Inc.
Insiders net bought $38.00M in 90 days; last 8-K filed Nov 2: bylaws or fiscal year change, other event.
Price
Chart by TradingView
Members see
- Signals: which strategies fired on ASPE, and the evidence behind each
- Options positioning: the levels dealers are hedged around
- Technicals: trend and momentum readings
- News: stories counted once across outlets
What it is
No 10-K on file. Funds and foreign issuers don't file one.
- Sector
- Life Sciences (SEC office)
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Headquarters
- San Diego, CA
- Incorporated in
- DE
- Fiscal year ends
- December
- Exchange
- None
- Fractional shares
- No
- Listed options
- No
- Filer category
- <br>Emerging growth company
- Shares outstanding
- Not reported.
- Filer (SEC EDGAR)
- EDGAR filing index
Key stats
Valuation
Valuation ratios use the live price. Free with an account.
Start free to see thisDeep value
- NCAV
- —
- NCAV per share
- —
- NNWC
- —
- NNWC per share
- —
These figures use the live price. Free with an account.
Expectations
- Free cash flow
- —
- Free cash growth, last 5 years
- —
- Revenue growth, last 5 years
- —
These figures use the live price. Free with an account.
Margins
- Gross
- —
- Operating
- —
- Net
- —
Returns
- ROE
- —
- ROA
- —
Health
- Current ratio
- —
- Debt/equity
- —
Growth the price implies: the yearly free cash flow growth that justifies today's value over 10 years, at a 10% discount rate, 3% growth after year 10. The market's assumption, not a forecast.
Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
No quarterly results reported by SEC for this filer.
- Cash (not reported by this company)
- —Cash: unreported by this company.
- Debt
- —
- Net cash
- —
- Current assets (not reported by this company)
- —Current assets: unreported by this company.
- Current liabilities (not reported by this company)
- —Current liabilities: unreported by this company.
- Working capital
- —
- Total liabilities (not reported by this company)
- —Total liabilities: unreported by this company.
- Assets (not reported by this company)
- —Assets: unreported by this company.
- Equity (not reported by this company)
- —Equity: unreported by this company.
SEC data as of Nov 3, 2026
Ten years
No annual results reported by SEC for this filer.
Company filings
1 offering filing in 12 months
events
- Bylaws or fiscal year changeOther eventNov 28-K
Insiders, politicians and funds
Insider trades, last 90 days
ARCH Venture Fund X, L.P.
10% owner
Buy$19,999,995Nov 2, 9:50 PM ET
ARCH Venture Partners XIV, L.P.
10% owner
Buy$18,000,000Nov 2, 9:46 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
None of the tracked funds held this at their last 13F.
Short interest
Hard to borrow: Alpaca will not lend it for shorting
Off-exchange short volume, 20 days
44.0%
Through Nov 2, 2026
Of the volume reported to FINRA's off-exchange facilities, market makers' hedging included. It is not short interest.
Short interest and short volume: FINRA
nakagai
Signals on ASPE come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Follow ASPE free
Comments · 0
No comments yet.